Artivion (AORT) 10-Q 31 Jul 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Jul. 18, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Central Index Key	0000784199
Entity Registrant Name	CRYOLIFE INC.
Entity Interactive Data Current	Yes
Entity File Number	1-13165
Entity Address, City or Town	Kennesaw
Entity Address, State or Province	GA
Entity Address, Address Line One	1655 Roberts Boulevard, NW
Entity Address, Postal Zip Code	30144
Entity Tax Identification Number	59-2417093
Entity Incorporation, State or Country Code	FL
City Area Code	770
Local Phone Number	419-3355
Trading Symbol	CRY
Title of 12(b) Security	Common Stock, $0.01 par value
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		37,495,602

Consolidated Statements Of Oper

Consolidated Statements Of Operations And Comprehensive (Loss) Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues:
Total revenues	$ 71,139	$ 68,496	$ 138,644	$ 130,444
Cost of products and preservation services:
Total cost of products and preservation services	24,173	22,645	47,405	45,365
Gross margin	46,966	45,851	91,239	85,079
Operating expenses:
General, administrative, and marketing	34,623	34,727	71,143	72,075
Research and development	5,841	5,719	11,389	11,089
Total operating expenses	40,464	40,446	82,532	83,164
Operating income	6,502	5,405	8,707	1,915
Interest expense	3,811	4,103	7,705	7,759
Interest income	(233)	(30)	(349)	(89)
Other expense, net	185	1,466	262	1,285
Income (loss) before income taxes	2,739	(134)	1,089	(7,040)
Income tax benefit	(93)	(360)	(1,446)	(3,411)
Net income (loss)	$ 2,832	$ 226	$ 2,535	$ (3,629)
Income (loss) per common share:
Basic	$ 0.08	$ 0.01	$ 0.07	$ (0.10)
Diluted	$ 0.07	$ 0.01	$ 0.07	$ (0.10)
Weighted-average common shares outstanding:
Basic	37,156	36,318	36,968	36,233
Diluted	37,838	37,249	37,789	36,233
Net income (loss)	$ 2,832	$ 226	$ 2,535	$ (3,629)
Foreign currency translation adjustments	2,995	(11,765)	(786)	(4,626)
Comprehensive income (loss)	5,827	(11,539)	1,749	(8,255)
Products [Member]
Revenues:
Total revenues	51,168	49,313	99,569	92,911
Cost of products and preservation services:
Total cost of products and preservation services	14,489	13,550	28,315	27,707
Preservation Services [Member]
Revenues:
Total revenues	19,971	19,183	39,075	37,533
Cost of products and preservation services:
Total cost of products and preservation services	$ 9,684	$ 9,095	$ 19,090	$ 17,658

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 39,747	$ 41,489
Restricted securities	508	747
Trade receivables, net	54,771	47,108
Other receivables	6,967	4,324
Inventories	45,422	45,478
Deferred preservation costs	32,416	33,174
Prepaid expenses and other	8,726	6,848
Total current assets	188,557	179,168
Property and equipment, net	30,823	31,028
Operating lease right-of-use assets, net	22,413
Goodwill	188,106	188,781
Acquired technology, net	113,567	118,184
Other intangibles, net	40,977	41,897
Deferred income taxes	3,975	4,111
Other	8,705	7,922
Total assets	597,123	571,091
Current liabilities:
Accounts payable	6,942	7,547
Accrued compensation	9,432	10,733
Current portion of long-term debt	1,164	1,160
Current maturities of operating leases	5,021
Taxes payable	2,489	2,250
Accrued expenses and other	12,420	12,833
Total current liabilities	37,468	34,523
Long-term debt	215,013	215,721
Non-current maturities of operating leases	19,241
Deferred income taxes	26,672	27,267
Other	16,576	18,513
Total liabilities	314,970	296,024
Commitments and contingencies
Shareholders' equity:
Preferred stock
Common stock (issued shares of 38,943 in 2019 and 38,463 in 2018)	389	385
Additional paid-in capital	265,694	260,361
Retained earnings	37,519	34,984
Accumulated other comprehensive (loss) income	(6,858)	(6,072)
Treasury stock at cost (shares of 1,484 in 2019 and 1,484 in 2018)	(14,591)	(14,591)
Total shareholders' equity	282,153	275,067
Total liabilities and shareholders' equity	$ 597,123	$ 571,091

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares shares in Thousands	Jun. 30, 2019	Dec. 31, 2018
Shareholders' equity:
Common stock, shares issued	38,943	38,463
Treasury stock at cost, shares	1,484	1,484

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Net cash flows from operating activities:
Net income (loss)	$ 2,535	$ (3,629)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	8,731	9,105
Non-cash compensation	4,119	3,117
Deferred income taxes	(301)	(2,871)
Other non-cash adjustments to income (loss)	4,032	1,478
Changes in operating assets and liabilities:
Receivables	(10,446)	(6,720)
Inventories and deferred preservation costs	262	1,125
Prepaid expenses and other assets	(3,131)	(2,257)
Accounts payable, accrued expenses, and other liabilities	(3,894)	(8,308)
Net cash flows provided by (used in) operating activities	1,907	(8,960)
Net cash flows from investing activities:
Capital expenditures	(3,344)	(3,353)
Other	(302)	(278)
Net cash flows used in investing activities	(3,646)	(3,631)
Net cash flows from financing activities:
Repayment of term loan	(1,393)	(1,400)
Proceeds from exercise of stock options and issuance of common stock	3,582	943
Redemption and repurchase of stock to cover tax withholdings	(2,664)	(1,811)
Other	(349)	(692)
Net cash flows used in financing activities	(824)	(2,960)
Effect of exchange rate changes on cash, cash equivalents, and restricted securities	582	517
Decrease in cash, cash equivalents, and restricted securities	(1,981)	(15,034)
Cash, cash equivalents, and restricted securities beginning of year	42,236	40,753
Cash, cash equivalents, and restricted securities end of year	$ 40,255	$ 25,719

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid In Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2017	$ 376	$ 249,935	$ 37,609	$ 1,857	$ (12,719)	$ 277,058
Balance, shares at Dec. 31, 2017	37,618				(1,386)
Net income (loss) | ASU 606 [Member]			(3,629)			(3,629)
Net income (loss)						(3,629)
Foreign currency translation income (loss) | ASU 606 [Member]				(4,626)		(4,626)
Foreign currency translation income (loss)						(4,626)
Comprehensive income (loss) | ASU 606 [Member]						(8,040)
Comprehensive income (loss)						(8,255)
Equity compensation	$ 1	3,354				3,355
Equity compensation, shares	289
Exercise of options	$ 5	2,222			$ (1,872)	355
Exercise of options, shares	354				(98)
Employee stock purchase plan		588				588
Employee stock purchase plan, shares	37
Redemption and repurchase of stock to cover tax withholdings		(1,811)				(1,811)
Redemption and repurchase of stock to cover tax withholdings, shares	(94)
Balance at Jun. 30, 2018	$ 382	254,288	34,195	(2,769)	$ (14,591)	271,505
Balance, shares at Jun. 30, 2018	38,204				(1,484)
Balance at Mar. 31, 2018	$ 381	252,251	33,969	8,996	$ (14,591)	281,006
Balance, shares at Mar. 31, 2018	38,115				(1,484)
Net income (loss)			226			226
Foreign currency translation income (loss)				(11,765)		(11,765)
Comprehensive income (loss)						(11,539)
Equity compensation		2,001				2,001
Equity compensation, shares	64
Exercise of options	$ 1	336				337
Exercise of options, shares	37
Redemption and repurchase of stock to cover tax withholdings		(300)				(300)
Redemption and repurchase of stock to cover tax withholdings, shares	(12)
Balance at Jun. 30, 2018	$ 382	254,288	34,195	(2,769)	$ (14,591)	271,505
Balance, shares at Jun. 30, 2018	38,204				(1,484)
Balance at Mar. 31, 2018	$ 381	252,251	33,969	8,996	$ (14,591)	281,006
Balance, shares at Mar. 31, 2018	38,115				(1,484)
Balance at Jun. 30, 2019	$ 389	265,694	37,519	(6,858)	$ (14,591)	282,153
Balance, shares at Jun. 30, 2019	38,943				(1,484)
Cumulative effect of adjustment | ASU 606 [Member]			215			215
Balance at Dec. 31, 2018	$ 385	260,361	34,984	(6,072)	$ (14,591)	275,067
Balance, shares at Dec. 31, 2018	38,463				(1,484)
Net income (loss)			2,535			2,535
Foreign currency translation income (loss)				(786)		(786)
Comprehensive income (loss)						1,749
Equity compensation	$ 2	4,417				4,419
Equity compensation, shares	245
Exercise of options	$ 3	3,001				3,004
Exercise of options, shares	301
Employee stock purchase plan		578				578
Employee stock purchase plan, shares	25
Redemption and repurchase of stock to cover tax withholdings	$ (1)	(2,663)				(2,664)
Redemption and repurchase of stock to cover tax withholdings, shares	(91)
Balance at Jun. 30, 2019	$ 389	265,694	37,519	(6,858)	$ (14,591)	282,153
Balance, shares at Jun. 30, 2019	38,943				(1,484)
Balance at Mar. 31, 2019	$ 388	261,991	34,687	(9,853)	$ (14,591)	272,622
Balance, shares at Mar. 31, 2019	38,756				(1,484)
Net income (loss)			2,832			2,832
Foreign currency translation income (loss)				2,995		2,995
Comprehensive income (loss)						5,827
Equity compensation		2,439				2,439
Equity compensation, shares	40
Exercise of options	$ 2	1,551				1,553
Exercise of options, shares	156
Redemption and repurchase of stock to cover tax withholdings	$ (1)	(287)				(288)
Redemption and repurchase of stock to cover tax withholdings, shares	(9)
Balance at Jun. 30, 2019	$ 389	$ 265,694	$ 37,519	$ (6,858)	$ (14,591)	$ 282,153
Balance, shares at Jun. 30, 2019	38,943				(1,484)

Basis Of Presentation

Basis Of Presentation	6 Months Ended
	Jun. 30, 2019
Basis Of Presentation [Abstract]
Basis Of Presentation	1. Basis of Presentation Overview The accompanying summary consolidated financial statements include the accounts of CryoLife, Inc. and its subsidiaries (“CryoLife,” the “Company,” “we,” or “us”). All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying Summary Consolidated Balance Sheet as of December 31, 2018 has been derived from audited financial statements. The accompanying unaudited summary consolidated financial statements as of, and for the three and six months ended, June 30, 2019 and 2018 have been prepared in accordance with (i) accounting principles generally accepted in the U.S. for interim financial information and (ii) the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, such statements do not include all of the information and disclosures required by accounting principles generally accepted in the U.S. for a complete presentation of financial statements. In the opinion of management, all adjustments (including those of a normal, recurring nature) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. These summary consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in CryoLife’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on February 26, 2019. New Accounting Standards Recently Adopted As of January 1, 2019 we adopted the Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”). The final guidance requires lessees to recognize a right-of-use asset and a lease liability for all leases (with the exception of short-term leases) at the commencement date and recognize expenses on their income statements similar to former Topic 840, Leases . We used the modified retrospective approach, which allows application of the standard at the adoption date rather than at the beginning of the earliest comparative period presented. The adoption of this standard resulted in the recognition of operating lease agreements with a net present value of $ 22.7 million and corresponding right-of-use assets obtained in the same amount at January 1, 2019. See Note 7 for further discussion of leases. Not Yet Effective In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASC Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods and early adoption is permitted. We are in the process of evaluating the effect that the adoption of this standard will have on our financial position and results of operations.

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2019
Financial Instruments [Abstract]
Financial Instruments	2. Financial Instruments The following is a summary of our financial instruments measured at fair value (in thousands): June 30, 2019 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 1,458 $ -- $ -- $ 1,458 Restricted securities: Money market funds 508 -- -- 508 Total assets $ 1,966 $ -- $ -- $ 1,966 December 31, 2018 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 1,445 $ -- $ -- $ 1,445 Restricted securities: Money market funds 747 -- -- 747 Total assets $ 2,192 $ -- $ -- $ 2,192 We used prices quoted from our investment advisors to determine the Level 1 valuation of our investments in money market funds .

Cash Equivalents And Restricted

Cash Equivalents And Restricted Securities	6 Months Ended
	Jun. 30, 2019
Cash Equivalents And Restricted Securities [Abstract]
Cash Equivalents And Restricted Securities	3. Cash Equivalents and Restricted Securities The following is a summary of cash equivalents and restricted securities (in thousands): Unrealized Estimated Holding Market June 30, 2019 Cost Basis Gains Value Cash equivalents: Money market funds $ 1,458 $ -- $ 1,458 Restricted securities: Money market funds 508 -- 508 Unrealized Estimated Holding Market December 31, 2018 Cost Basis Gains Value Cash equivalents: Money market funds $ 1,445 $ -- $ 1,445 Restricted securities: Money market funds 747 -- 747 As of June 30, 2019 and December 31, 2018 all of our money market funds were designated as short-term restricted securities due to a contractual commitment to hold the securities as pledged collateral relating primarily to international tax obligations. There were no gross realized gains or losses on cash equivalents and restricted securities in the three and six months ended June 30, 2019 and 2018. As of June 30, 2019 $ 508,000 of our restricted securities had a maturity date within three months . As of December 31, 2018 $ 512,000 of our restricted securities had a maturity date within three months and $ 235,000 had a maturity date between three months and one year .

Inventories And Deferred Preser

Inventories And Deferred Preservation Costs	6 Months Ended
	Jun. 30, 2019
Inventories And Deferred Preservation Costs [Abstract]
Inventories And Deferred Preservation Costs	4. Inventories and Deferred Preservation Costs Inventories at June 30, 2019 and December 31, 2018 were comprised of the following (in thousands): June 30, December 31, 2019 2018 Raw materials and supplies $ 18,496 $ 17,381 Work-in-process 4,382 3,858 Finished goods 22,544 24,239 Total inventories $ 45,422 $ 45,478 Deferred preservation costs at June 30, 2019 and December 31, 2018 were comprised of the following (in thousands): June 30, December 31, 2019 2018 Cardiac tissues $ 16,171 $ 15,972 Vascular tissues 16,245 17,202 Total deferred preservation costs $ 32,416 $ 33,174 We maintain consignment inventory of our On-X Life Technologies Holdings, Inc. (“On-X”) heart valves at domestic hospital locations and On-X heart valves and JOTEC products at international hospital locations to facilitate usage. We retain title and control over this consignment inventory until the device is implanted, at which time we invoice the hospital and recognize revenue. As of June 30, 2019 we had $ 13.0 million in consignment inventory, with approximately 50 % in domestic locations and 50 % in foreign locations. As of December 31, 2018 we had $ 11.2 million in consignment inventory, with approximately 55 % in domestic locations and 45 % in foreign locations.

Goodwill And Other Intangible A

Goodwill And Other Intangible Assets	6 Months Ended
	Jun. 30, 2019
Goodwill And Other Intangible Assets [Abstract]
Goodwill And Other Intangible Assets	5. Goodwill and Other Intangible Assets Indefinite Lived Intangible Assets As of June 30, 2019 and December 31, 2018 the carrying values of our indefinite lived intangible assets were as follows (in thousands): June 30, December 31, 2019 2018 Goodwill $ 188,106 $ 188,781 In-process R&D 9,325 9,382 Procurement contracts and agreements 2,013 2,013 Trademarks 844 844 We monitor the phases of development of our acquired in-process R&D projects, including the risks associated with further development and the amount and timing of benefits expected to be derived from the completed projects. Incremental costs associated with development are charged to expense as incurred. Capitalized costs are amortized over the estimated useful life of the developed asset once completed. Our in-process R&D projects are reviewed for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. Based on our experience with similar agreements, we believe that our acquired procurement contracts and agreements have indefinite useful lives, as we expect to continue to renew these contracts for the foreseeable future. We believe that our trademarks have indefinite useful lives as we currently anticipate that our trademarks will contribute to our cash flows indefinitely. As of June 30, 2019 and December 31, 2018 our entire goodwill balance was related to our Medical Devices segment. Medical Devices Segment Balance as of December 31, 2018 $ 188,781 Revaluation of goodwill denominated in foreign currency ( 675 ) Balance as of June 30, 2019 $ 188,106 Definite Lived Intangible Assets As of June 30, 2019 and December 31, 2018 the gross carrying values, accumulated amortization, and approximate amortization period of our definite lived intangible assets were as follows (in thousands): Gross Carrying Accumulated Amortization June 30, 2019 Value Amortization Period Acquired technology $ 134,408 $ 20,841 11 – 22 Years Customer lists and relationships 31,157 5,825 13 – 22 Years Distribution and manufacturing rights and know-how 4,059 2,251 11 – 15 Years Patents 3,626 3,030 17 Years Other 1,496 437 3 – 5 Years Gross Carrying Accumulated Amortization December 31, 2018 Value Amortization Period Acquired technology $ 134,999 $ 16,815 11 – 22 Years Customer lists and relationships 31,169 5,068 13 – 22 Years Distribution and manufacturing rights and know-how 4,059 2,107 11 – 15 Years Patents 3,656 2,970 17 Years Other 1,154 235 3 – 5 Years Amortization Expense The following is a summary of amortization expense as recorded in general, administrative, and marketing expenses on our Summary Consolidated Statement of Operations and Comprehensive Income (Loss) (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Amortization expense $ 2,557 $ 2,753 $ 5,136 $ 5,487 As of June 30, 2019 scheduled amortization of intangible assets for the next five years is as follows (in thousands): Remainder of 2019 2020 2021 2022 2023 2024 Total Amortization expense $ 5,186 $ 10,208 $ 10,185 $ 9,639 $ 9,227 $ 9,005 $ 53,450

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2019
Income Taxes [Abstract]
Income Taxes	6. Income Taxes Income Tax Expense Our effective income tax rate was a benefit of 3 % and 133 % for the three and six months ended June 30, 2019, respectively, as compared to a benefit of 269 % and 48 % for the three and six months ended June 30, 2018, respectively. The change in the tax rate for the three and six months ended June 30, 2019 is primarily due to a change in pre-tax book income for the three and six months ended June 30, 2019 as compared to the three and six months ended June 30, 2018. The income tax rate for the three and six months ended June 30, 2019 was impacted by excess tax benefit deductions related to stock compensation, which increased income tax benefits by approximately $ 700,000 and $ 1.9 million, respectively. The income tax rate was also favorably impacted by losses in high rate jurisdictions, partially offset by unfavorable impacts of non-deductible operating expenses and executive compensation expenses. The income tax rate for the three and six months ended June 30, 2018 was impacted by excess tax benefit deductions related to stock compensation, which increased income tax benefits by approximately $ 300,000 and $ 1.4 million, respectively, and losses in high rate jurisdictions. These factors were partially offset by impacts of non-deductible operating expenses and executive compensation expenses. Deferred Income Taxes We generate deferred tax assets primarily as a result of write-downs of inventory and deferred preservation costs, accruals for product and tissue processing liability claims, investment and asset impairments, and operating losses. We acquired significant deferred tax assets, primarily net operating loss carryforwards, from our acquisitions of JOTEC GmbH (“JOTEC”) and its subsidiaries in 2017, On-X in 2016, Hemosphere, Inc. in 2012, and Cardiogenesis Corporation in 2011. We believe utilization of these net operating losses will not have a material impact on income taxes for the 2019 tax year. As of June 30, 2019 we maintained a total of $ 3.9 million in valuation allowances against deferred tax assets, primarily related to state net operating loss carryforwards, and had a net deferred tax liability of $ 22.7 million. As of December 31, 2018 we had a total of $ 3.4 million in valuation allowances against deferred tax assets, primarily related to state net operating loss carryforwards, and a net deferred tax liability of $ 23.2 million.

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	7. Leases In February 2016 the FASB amended its ASC and created a new Topic 842, Leases. The final guidance requires lessees to recognize a right-of-use asset and a lease liability for all long-term leases at the commencement date and recognize expenses on their statements of income similar to the former Topic 840, Leases. It is effective for fiscal years and interim periods beginning after December 15, 2018 and early adoption was permitted. We adopted ASC 842, Leases effective January 1, 2019 using the modified retrospective approach, which allows application of the standard at the adoption date rather than at the beginning of the earliest comparative period presented. Therefore, no changes have been made to the 2018 financial statements. The adoption of this standard resulted in the recognition of operating lease agreements with a net present value of $ 22.7 million, and corresponding right-of-use assets obtained in the same amount, at January 1, 2019. The leases were recognized with a weighted average discount rate of 5.5 % and a weighted average remaining lease term of six years . In addition, deferred rent obligations of approximately $ 2.4 million recognized under prior lease rules were offset against the corresponding right-of-use asset and will be reflected in amortization over the remaining life of the lease. Our leases had remaining lease terms of one year up to 11 years, some of which had options to extend the leases for up to 29 years and one lease contained a termination option with a two year notice requirement. The adoption of the new leasing standard had no significant impact on covenants or other provisions of our current term and revolver loan facility agreements. We exercised judgment in the adoption of the new leasing standard, including the determination of whether a financial arrangement includes a lease and in determining the appropriate discount rates to be applied to leases based on our general collateralized credit standing and the geographical market considerations impacting lease rates across all locations. When available, we use the implicit discount rate in the lease contract to discount lease payments to present value. If an implicit discount rate is not available in the lease contract, we used our incremental borrowing rate. We elected the package of practical expedients permitted under the transition guidance of the new leasing standard which includes a provision which allows us to carry forward the historical lease classification of identified leasing arrangements and not reassess (i) classification for any existing leases, (ii) whether any expired or existing agreements are or contain a lease, or (iii) whether any initial direct costs qualified for capitalization. We have also elected the practical expedients that allow us to omit leases with initial terms of 12 months or less from our balance sheet, which are expensed on a straight-line basis over the life of the lease. We have elected not to separate lease and non-lease components for future leases. Our operating and finance lease liabilities result from the lease of land and buildings that comprise our corporate headquarters, various manufacturing facilities and related space, leases on company vehicles, and leases on a variety of office and other equipment. Our leases do not include terms or conditions which would result in variable lease payments other than for small office equipment leases with an additional charge for volume of usage. These incremental payments are excluded from our calculation of lease liability and the related right-of-use asset. We do not include option terms in the determination of lease liabilities and the related right-of-use assets until we determine the exercise of the option is reasonably certain. Our leases do not contain residual value guarantee provisions or other restrictions or financial covenant provisions. On March 8, 2019 we executed a modification to extend the lease of our On-X manufacturing facilities. This modification resulted in an increase in the net present value and corresponding right-of-use asset of $ 3.7 million, using a discount rate of 5.83 %. We have not executed any material lease arrangements which have not commenced. We do not have any related party leasing arrangements. We sublease, on an operating lease basis, two unused office space facilities near our corporate office. Total annual rental income for these facilities is approximately $ 910,000 . Supplemental consolidated balance sheet information related to leases was as follows (in thousands, except lease term and discount rate): Operating leases: June 30, 2019 Operating lease right-of-use assets $ 24,828 Accumulated amortization ( 2,415 ) Operating lease right-of-use assets, net $ 22,413 Current maturities of operating leases $ 5,021 Non-current maturities of operating lease 19,241 Total operating lease liabilities $ 24,262 Finance leases: Property and equipment, at cost $ 7,627 Accumulated amortization ( 1,302 ) Property and equipment, net $ 6,325 Current maturities of finance leases $ 665 Non-current maturities of finance leases 5,611 Total finance lease liabilities $ 6,276 Weighted average remaining lease term (in years): Operating leases 5.9 Finance leases 11 Weighted average discount rate: Operating leases 5.5 % Finance leases 2.0 % Current maturities of finance leases are included as a component of Accrued Expenses and Other and non-current maturities of finance leases are included as a component of Other Long-Term Liabilities on our Summary Consolidated Balance Sheets. A summary of lease expenses for our finance and operating leases included in General, Administrative, and Marketing Expenses on our Summary Consolidated Statements of Operations and Comprehensive Income (Loss) are as follows (in thousands): Three Months Ended Six Months Ended June 30, 2019 June 30, 2019 Amortization of property and equipment $ 209 $ 420 Interest expense on finance leases 31 63 Total finance lease expense 240 483 Operating lease expense 1,589 3,153 Short-term lease expense - - Sublease income ( 226 ) ( 452 ) Total lease expense $ 1,603 $ 3,184 A summary of our supplemental cash flow information is as follows (in thousands): Six Months Ended Cash paid for amounts included in the measurement of lease liabilities: June 30, 2019 Operating cash flows for finance leases $ 64 Operating cash flows for operating leases 3,311 Financing cash flows for finance leases 350 Future minimum lease payments and sublease rental income are as follows (in thousands): Finance Operating Sublease Leases Leases Income Remainder of 2019 $ 437 $ 2,941 $ 456 2020 676 6,275 921 2021 637 5,802 930 2022 582 3,418 380 2023 582 2,327 -- Thereafter 4,075 7,411 -- Total minimum lease payments $ 6,989 $ 28,174 $ 2,687 Less amount representing interest ( 713 ) ( 3,912 ) Present value of net minimum lease payments 6,276 24,262 Less current maturities ( 665 ) ( 5,021 ) Lease liabilities, less current maturities $ 5,611 $ 19,241

Debt

Debt	6 Months Ended
	Jun. 30, 2019
Debt [Abstract]
Debt	8. Debt Credit Agreement On December 1, 2017 we entered into a credit and guaranty agreement for a new $ 255.0 million senior secured credit facility, consisting of a $ 225.0 million secured term loan facility (the “Term Loan Facility”) and a $ 30.0 million secured revolving credit facility (“the Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Agreement”). We and each of our existing domestic subsidiaries (subject to certain exceptions and exclusions) guarantee the obligations under the Credit Agreement (the “Guarantors”). The Credit Agreement is secured by a security interest in substantially all existing and after-acquired real and personal property (subject to certain exceptions and exclusions) of us and the Guarantors. On December 1, 2017 we borrowed the entire $ 225.0 million Term Loan Facility. The proceeds of the Term Loan Facility were used along with cash on hand and shares of CryoLife common stock to (i) fund the acquisition of JOTEC and its subsidiaries (the “JOTEC Acquisition”), (ii) pay certain fees and expenses related to the JOTEC Acquisition and the Credit Agreement, and (iii) pay the outstanding balance of our prior credit facility. The Revolving Credit Facility is undrawn following the JOTEC Acquisition and may be used for working capital, capital expenditures, acquisitions permitted under the Credit Agreement, and other general corporate purposes pursuant to the terms of the Credit Agreement. The loan under the Term Loan Facility is repayable on a quarterly basis according to the amortization provisions set forth in the Credit Agreement. We have the right to repay the loan under the Credit Agreement in whole or in part at any time. Amounts repaid in respect of the loan under the Term Loan Facility may not be reborrowed. Amounts repaid in respect of the loan under the Revolving Credit Facility may be reborrowed. All outstanding principal and interest in respect of (i) the Term Loan Facility must be repaid on or before December 1, 2024 and (ii) the Revolving Credit Facility must be repaid on or before December 1, 2022 . In October 2018 we finalized an amendment to the Credit Agreement to reprice interest rates, resulting in a reduction in the interest rate margins over base rates on the Term Loan Facility. The loan under the Term Loan Facility bears interest, at our option, at a floating annual rate equal to either the base rate, plus a margin of 2.25 %, or LIBOR, plus a margin of 3.25 %. Prior to the repricing, the optional floating annual rate was equal to either the base rate plus a margin of 3.00 %, or LIBOR, plus a margin of 4.00 %. The loan under the Revolving Credit Facility bears interest, at our option, at a floating annual rate equal to either the base rate, plus a margin of between 3.00 % and 3.25 %, depending on our consolidated leverage ratio, or LIBOR, plus a margin of between 4.00 % and 4.25 %, depending on our consolidated leverage ratio. While a payment or bankruptcy event of default exists, we are obligated to pay a per annum default rate of interest of 2.00 % in excess of the interest rate otherwise payable with respect to the overdue principal amount of any loans outstanding and overdue interest payments and other overdue fees and amounts. As of June 30, 2019 the aggregate interest rate was 5.58 % per annum. We are obligated to pay an unused commitment fee equal to 0.50 % of the unutilized portion of the revolving loans. In addition, we are also obligated to pay other customary fees for a credit facility of this size and type. The Credit Agreement contains certain customary affirmative and negative covenants, including covenants that limit our ability and the ability of our subsidiaries to, among other things, grant liens, incur debt, dispose of assets, make loans and investments, make acquisitions, make certain restricted payments, merge or consolidate, change their business or accounting or reporting practices, in each case subject to customary exceptions for a credit facility of this size and type. In addition, with respect to the Revolving Credit Facility, when the principal amount of loans outstanding thereunder is in excess of 25 % of the Revolving Credit Facility, the Credit Agreement requires us to comply with a specified maximum first lien net leverage ratio. The Credit Agreement prohibits the payment of certain restricted payments, including cash dividends. The Credit Agreement includes certain customary events of default that include, among other things, non-payment of principal, interest, or fees; inaccuracy of representations and warranties; breach of covenants; cross-default to certain material indebtedness; bankruptcy and insolvency; and change of control. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued but unpaid interest under the Credit Agreement immediately due and payable and may exercise the other rights and remedies provided under the Credit Agreement and related loan documents. As of June 30, 2019 and December 31, 2018 there were no outstanding balances on our Revolving Credit Facility and the remaining availability was $ 30.0 million. Government Supported Bank Debt In June 2015 JOTEC obtained two loans from Sparkasse Zollernalb, which are government sponsored by the Kreditanstalt für Wiederaufbau Bank (“KFW”). Both KFW loans have a term of nine years and the interest rates are 2.45 % and 1.40 %. Loan Balances The short-term and long-term balances of our term loan and other borrowings were as follows (in thousands): June 30, December 31, 2019 2018 Term loan balance $ 221,625 $ 222,750 2.45% Sparkasse Zollernalb (KFW Loan 1) 1,169 1,318 1.40% Sparkasse Zollernalb (KFW Loan 2) 1,637 1,885 Total loan balance 224,431 225,953 Less unamortized loan origination costs ( 8,254 ) ( 9,072 ) Net borrowings 216,177 216,881 Less short-term loan balance ( 1,164 ) ( 1,160 ) Long-term loan balance $ 215,013 $ 215,721 Interest Expense Interest expense was $ 3.8 million and $ 7.7 million for the three and six months ended June 30, 2019, respectively, as compared to $ 4.1 million and $ 7.8 million for the three and six months ended June 30, 2018, respectively. Interest expense includes interest on debt and uncertain tax positions in both periods.

Commitments And Contingencies

Commitments And Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments And Contingencies [Abstract]
Commitments And Contingencies	9. Commitments and Contingencies Liability Claims Our estimated unreported loss liability was $ 1.9 million and $ 1.7 million as of June 30, 2019 and December 31, 2018, respectively. As of June 30, 2019 and December 31, 2018, the related recoverable insurance amounts were $ 897,000 and $ 693,000 , respectively. We accrue our estimate of unreported product and tissue processing liability claims as a component of other long - term liabilities and record the related recoverable insurance amount as a component of other long - term assets, as appropriate. Further analysis indicated that the estimated liability as of June 30, 2019 could have been as high as $ 3.7 million, after including a reasonable margin for statistical fluctuations calculated based on actuarial simulation techniques. Employment Agreements The employment agreement of our Chairman, President, and Chief Executive Officer (“CEO”), Mr. J. Patrick Mackin, provides for a severance payment, which would become payable upon the occurrence of certain employment termination events, including termination by us without cause. PerClot Technology On September 28, 2010 we entered into a worldwide distribution agreement (the “Distribution Agreement”) and a license and manufacturing agreement (the “License Agreement”) with Starch Medical, Inc. (“SMI”), for PerClot ® , a polysaccharide hemostatic agent used in surgery. The Distribution Agreement has a term of 15 years but can be terminated for any reason before the expiration date by us by providing 180 days’ notice. The Distribution Agreement also contains minimum purchase requirements that expire upon the termination of the Distribution Agreement or following U.S. regulatory approval for PerClot. Separate and apart from the terms of the Distribution Agreement, pursuant to the License Agreement, as amended by a September 2, 2011 technology transfer agreement, we can manufacture and sell PerClot, assuming appropriate regulatory approvals, in the U.S. and certain other jurisdictions and may be required to pay royalties to SMI at certain rates on net revenues of products. We may make contingent payments to SMI of up to $ 1.0 million if certain U.S. regulatory and certain commercial milestones are achieved. We are conducting our pivotal clinical trial to gain approval to commercialize PerClot for surgical indications in the U.S. Enrollment was completed in January 2019. We anticipate Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) in early 2020. As of June 30, 2019 we had $ 1.5 million in prepaid royalties, $ 2.2 million in intangible assets, net, and $ 1.3 million in property and equipment, net on our Summary Consolidated Balance Sheets related to the PerClot product line. If we do not ultimately pursue or receive FDA approval to commercialize PerClot in the U.S., these assets could be materially impaired in future periods.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2019
Revenue Recognition [Abstract]
Revenue Recognition	10. Revenue Recognition Sources of Revenue We have identified the following revenues disaggregated by revenue source:  Domestic Hospitals – direct sales of products and preservation services.  International Hospitals – direct sales of products and preservation services.  International Distributors – generally these contracts specify a geographic area that the distributor will service, terms and conditions of the relationship, and purchase targets for the next calendar year.  CardioGenesis Cardiac Laser Console Trials and Sales – CardioGenesis cardiac trialed laser consoles are delivered under separate agreements. For the three and six months ended June 30, 2019 and 2018 the sources of revenue were as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 (Unaudited) (Unaudited) Domestic hospitals $ 36,344 $ 35,139 $ 71,955 $ 68,682 International hospitals 22,532 21,902 43,102 40,951 International distributors 10,365 9,877 19,975 17,887 CardioGenesis cardiac laser therapy 1,898 1,578 3,612 2,924 Total sources of revenue $ 71,139 $ 68,496 $ 138,644 $ 130,444 Also see segment and geographic disaggregation information in Note 13 below. Contract Balances We may generate contract assets during the pre-delivery design and manufacturing stage of E-xtra DESIGN ENGINEERING product order fulfillment. We assess the balance related to any arrangements in process and determine if the enforceable right to payment creates a material contract asset requiring disclosure. No material arrangements in process existed as of June 30, 2019 and 2018. We also incur contract obligations on general customer purchase orders that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product or service, we have determined that the balance related to these contract obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. The value of orders accepted but unfulfilled as of June 30, 2019 and 2018 were not material.

Stock Compensation

Stock Compensation	6 Months Ended
	Jun. 30, 2019
Stock Compensation [Abstract]
Stock Compensation	11. Stock Compensation Overview We have stock option and stock incentive plans for employees and non-employee Directors that provide for grants of restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”), and options to purchase shares of our common stock at exercise prices generally equal to the fair value of such stock at the dates of grant. We also maintain a shareholder-approved Employee Stock Purchase Plan (the “ESPP”) for the benefit of our employees. The ESPP allows eligible employees to purchase common stock on a regular basis at the lower of 85 % of the market price at the beginning or end of each offering period. Equity Grants During the six months ended June 30, 2019 the Compensation Committee of our Board of Directors (the “Committee”) authorized awards from approved stock incentive plans of RSUs to certain employees, RSAs to non-employee Directors and RSAs and PSUs to certain Company officers, which, assuming that performance under the PSUs were to be achieved at target levels, together totaled 492,000 shares and had an aggregate grant date market value of $ 14.6 million. Two types of PSUs were granted in 2019, one with a short-term performance component and the other with a long-term performance component. If performance thresholds are met, the short-term PSUs granted in 2019 represent the right to receive up to 150 % of the target number of shares of common stock. The performance component of the short-term PSU awards granted in 2019 is based on attaining specified levels of adjusted earnings before interest, taxes, depreciation, and amortization, (“EBITDA”), as defined in the PSU grant documents, for the 2019 calendar year. If performance thresholds are met, the long-term PSUs granted in 2019 represent the right to receive up to 288 % of the target number of shares of common stock. The performance component of the long-term PSU awards granted in 2019 is based on attaining specified levels of adjusted revenue growth and gross margin, as defined in the PSU grant document, for the years 2019 through 2023. We currently believe that achievement of the performance component for both types of PSUs is probable, and we reevaluate this likelihood on a quarterly basis. During the six months ended June 30, 2018 the Committee authorized awards from approved stock incentive plans of RSUs to certain employees, RSAs to non-employee Directors and RSAs and PSUs to certain Company officers, which, including PSUs at target levels, together totaled 305,000 shares of common stock and had an aggregate grant date market value of $ 6.8 million. The PSUs granted in 2018 represented the right to receive up to 150 % of the target number of shares of common stock based on meeting performance thresholds. The performance component of PSU awards granted in 2018 was based on attaining specified levels of adjusted EBITDA, as defined in the PSU grant documents, for the 2018 calendar year. The PSUs granted in 2018 earned 80 % of the target number of shares. The Committee authorized, from approved stock incentive plans, grants of stock options to purchase a total of 169,000 and 219,000 shares to certain Company officers during the six months ended June 30, 2019 and 2018, respectively. The exercise prices of the options were equal to the closing stock prices on their respective grant dates. Employees purchased common stock totaling 24,000 shares and 36,000 shares in the six months ended June 30, 2019 and 2018, respectively, through the ESPP. There were no purchases of shares through the ESPP during the three months ended June 30, 2019 and 2018. Stock Compensation Expense The following weighted - average assumptions were used to determine the fair value of options and shares purchased under the ESPP: Three Months Ended Six Months Ended June 30, 2019 June 30, 2019 Stock Options ESPP Stock Options ESPP Expected life N/A 0.5 Years 5.0 Years 0.5 Years Expected stock price volatility N/A 0.39 0.40 0.39 Risk-free interest rate N/A 2.56 % 2.54 % 2.56 % The following table summarizes total stock compensation expenses prior to the capitalization of amounts into deferred preservation and inventory costs (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 RSA, RSU, and PSU expense $ 1,936 $ 1,521 $ 3,446 $ 2,469 Stock option and ESPP expense 502 483 973 889 Total stock compensation expense $ 2,438 $ 2,004 $ 4,419 $ 3,358 Included in the total stock compensation expense, as applicable in each period, were expenses related to RSAs, RSUs, PSUs, and stock options issued in each respective year, as well as those issued in prior periods that continue to vest during the period, and compensation related to the ESPP. These amounts were recorded as stock compensation expense and were subject to our normal allocation of expenses to inventory costs and deferred preservation costs. We capitalized $ 168,000 and $ 300,000 in the three and six months ended June 30, 2019, respectively, and $ 132,000 and $ 238,000 in the three and six months ended June 30, 2018, respectively, of the stock compensation expense into our inventory costs and deferred preservation costs. As of June 30, 2019 we had total unrecognized compensation costs of $ 16.1 million related to RSAs, RSUs, and PSUs and $ 2.8 million related to unvested stock options. As of June 30, 2019 this expense is expected to be recognized over a weighted-average period of 2.8 years for PSUs, 2.0 years for stock options, 1.9 years for RSUs, and 1.5 years for RSAs.

Income (Loss) Per Common Share

Income (Loss) Per Common Share	6 Months Ended
	Jun. 30, 2019
Income (Loss) Per Common Share [Abstract]
Income (Loss) Per Common Share	12. Income (Loss) Per Common Share The following table sets forth the computation of basic and diluted income (loss) per common share (in thousands, except per share data): Three Months Ended Six Months Ended June 30, June 30, Basic income (loss) per common share 2019 2018 2019 2018 Net income (loss) $ 2,832 $ 226 $ 2,535 $ ( 3,629 ) Net (income) loss allocated to participating securities ( 19 ) ( 2 ) ( 18 ) 31 Net income (loss) allocated to common shareholders $ 2,813 $ 224 $ 2,517 $ ( 3,598 ) Basic weighted-average common shares outstanding 37,156 36,318 36,968 36,233 Basic income (loss) per common share $ 0.08 $ 0.01 $ 0.07 $ ( 0.10 ) Three Months Ended Six Months Ended June 30, June 30, Diluted income (loss) per common share 2019 2018 2019 2018 Net income (loss) $ 2,832 $ 226 $ 2,535 $ ( 3,629 ) Net (income) loss allocated to participating securities ( 18 ) ( 2 ) ( 18 ) 31 Net income (loss) allocated to common shareholders $ 2,814 $ 224 $ 2,517 $ ( 3,598 ) Basic weighted-average common shares outstanding 37,156 36,318 36,968 36,233 Effect of dilutive stock options and awards 682 931 821 -- Diluted weighted-average common shares outstanding 37,838 37,249 37,789 36,233 Diluted income (loss) per common share $ 0.07 $ 0.01 $ 0.07 $ ( 0.10 ) We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to loss per common share. Accordingly, for the three and six months ended June 30, 2019 stock options to purchase a weighted-average of 158,000 and 105,000 shares, respectively, were antidilutive and excluded from the calculation of diluted weighted-average common shares outstanding. For the three months ended June 30, 2018 stock options to purchase a weighted-average of 219,000 shares were antidilutive and excluded from the calculation of diluted weighted-average common shares outstanding. For the six months ended June 30, 2018 all stock options and awards were excluded from the calculation of diluted weighted-average common shares outstanding as these would be antidilutive due to the net loss.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2019
Segment Information [Abstract]
Segment Information	13. Segment Information We have two reportable segments organized according to our products and services: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. There are no intersegment revenues. The primary measure of segment performance, as viewed by our management, is segment gross margin or net external revenues less cost of products and preservation services. We do not segregate assets by segment; therefore, asset information is excluded from the segment disclosures below. The following table summarizes revenues, cost of products and preservation services, and gross margins for our operating segments (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Revenues: Medical devices $ 51,168 $ 49,313 $ 99,569 $ 92,911 Preservation services 19,971 19,183 39,075 37,533 Total revenues 71,139 68,496 138,644 130,444 Cost of products and preservation services: Medical devices 14,489 13,550 28,315 27,707 Preservation services 9,684 9,095 19,090 17,658 Total cost of products and preservation services 24,173 22,645 47,405 45,365 Gross margin: Medical devices 36,679 35,763 71,254 65,204 Preservation services 10,287 10,088 19,985 19,875 Total gross margin $ 46,966 $ 45,851 $ 91,239 $ 85,079 The following table summarizes net revenues by product and service (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Products: BioGlue $ 17,933 $ 17,069 $ 35,155 $ 33,039 JOTEC 17,208 17,205 33,162 31,665 On-X 12,410 11,888 24,141 22,197 CardioGenesis cardiac laser therapy 1,898 1,578 3,612 2,924 PerClot 784 968 1,834 1,940 PhotoFix 935 605 1,665 1,146 Total products 51,168 49,313 99,569 92,911 Preservation services: Cardiac tissue 10,500 9,055 19,430 17,158 Vascular tissue 9,471 10,128 19,645 20,375 Total preservation services 19,971 19,183 39,075 37,533 Total revenues $ 71,139 $ 68,496 $ 138,644 $ 130,444

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2019
Financial Instruments [Abstract]
Summary Of Financial Instruments Measured At Fair Value	June 30, 2019 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 1,458 $ -- $ -- $ 1,458 Restricted securities: Money market funds 508 -- -- 508 Total assets $ 1,966 $ -- $ -- $ 1,966 December 31, 2018 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 1,445 $ -- $ -- $ 1,445 Restricted securities: Money market funds 747 -- -- 747 Total assets $ 2,192 $ -- $ -- $ 2,192

Cash Equivalents And Restrict_2

Cash Equivalents And Restricted Cash And Securities (Tables)	6 Months Ended
	Jun. 30, 2019
Cash Equivalents And Restricted Securities [Abstract]
Summary Of Cash Equivalents And Restricted Securities	Unrealized Estimated Holding Market June 30, 2019 Cost Basis Gains Value Cash equivalents: Money market funds $ 1,458 $ -- $ 1,458 Restricted securities: Money market funds 508 -- 508 Unrealized Estimated Holding Market December 31, 2018 Cost Basis Gains Value Cash equivalents: Money market funds $ 1,445 $ -- $ 1,445 Restricted securities: Money market funds 747 -- 747

Inventories And Deferred Pres_2

Inventories And Deferred Preservation Costs (Tables)	6 Months Ended
	Jun. 30, 2019
Inventories And Deferred Preservation Costs [Abstract]
Schedule Of Inventories	June 30, December 31, 2019 2018 Raw materials and supplies $ 18,496 $ 17,381 Work-in-process 4,382 3,858 Finished goods 22,544 24,239 Total inventories $ 45,422 $ 45,478
Schedule Of Deferred Preservation Costs	June 30, December 31, 2019 2018 Cardiac tissues $ 16,171 $ 15,972 Vascular tissues 16,245 17,202 Total deferred preservation costs $ 32,416 $ 33,174

Goodwill And Other Intangible_2

Goodwill And Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Goodwill And Other Intangible Assets [Abstract]
Schedule Of Carrying Values Of Indefinite Lived Intangible Assets	June 30, December 31, 2019 2018 Goodwill $ 188,106 $ 188,781 In-process R&D 9,325 9,382 Procurement contracts and agreements 2,013 2,013 Trademarks 844 844
Schedule Of Goodwill By Reportable Segment	Medical Devices Segment Balance as of December 31, 2018 $ 188,781 Revaluation of goodwill denominated in foreign currency ( 675 ) Balance as of June 30, 2019 $ 188,106
Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Period Of Definite Lived Intangible Assets	Gross Carrying Accumulated Amortization June 30, 2019 Value Amortization Period Acquired technology $ 134,408 $ 20,841 11 – 22 Years Customer lists and relationships 31,157 5,825 13 – 22 Years Distribution and manufacturing rights and know-how 4,059 2,251 11 – 15 Years Patents 3,626 3,030 17 Years Other 1,496 437 3 – 5 Years Gross Carrying Accumulated Amortization December 31, 2018 Value Amortization Period Acquired technology $ 134,999 $ 16,815 11 – 22 Years Customer lists and relationships 31,169 5,068 13 – 22 Years Distribution and manufacturing rights and know-how 4,059 2,107 11 – 15 Years Patents 3,656 2,970 17 Years Other 1,154 235 3 – 5 Years
Summary Of Amortization Expense	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Amortization expense $ 2,557 $ 2,753 $ 5,136 $ 5,487
Scheduled Amortization Of Intangible Assets For Next Five Years	Remainder of 2019 2020 2021 2022 2023 2024 Total Amortization expense $ 5,186 $ 10,208 $ 10,185 $ 9,639 $ 9,227 $ 9,005 $ 53,450

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Schedule Of Supplemental Balance Sheet Information Related To Leases	Operating leases: June 30, 2019 Operating lease right-of-use assets $ 24,828 Accumulated amortization ( 2,415 ) Operating lease right-of-use assets, net $ 22,413 Current maturities of operating leases $ 5,021 Non-current maturities of operating lease 19,241 Total operating lease liabilities $ 24,262 Finance leases: Property and equipment, at cost $ 7,627 Accumulated amortization ( 1,302 ) Property and equipment, net $ 6,325 Current maturities of finance leases $ 665 Non-current maturities of finance leases 5,611 Total finance lease liabilities $ 6,276 Weighted average remaining lease term (in years): Operating leases 5.9 Finance leases 11 Weighted average discount rate: Operating leases 5.5 % Finance leases 2.0 %
Summary Of Lease Costs	Three Months Ended Six Months Ended June 30, 2019 June 30, 2019 Amortization of property and equipment $ 209 $ 420 Interest expense on finance leases 31 63 Total finance lease expense 240 483 Operating lease expense 1,589 3,153 Short-term lease expense - - Sublease income ( 226 ) ( 452 ) Total lease expense $ 1,603 $ 3,184
Schedule Of Supplemental Cash Flow Information Related To Leases	Six Months Ended Cash paid for amounts included in the measurement of lease liabilities: June 30, 2019 Operating cash flows for finance leases $ 64 Operating cash flows for operating leases 3,311 Financing cash flows for finance leases 350
Schedule Of Minimum Lease Payments For Finance, Operating, And Sublease Income Leases	Finance Operating Sublease Leases Leases Income Remainder of 2019 $ 437 $ 2,941 $ 456 2020 676 6,275 921 2021 637 5,802 930 2022 582 3,418 380 2023 582 2,327 -- Thereafter 4,075 7,411 -- Total minimum lease payments $ 6,989 $ 28,174 $ 2,687 Less amount representing interest ( 713 ) ( 3,912 ) Present value of net minimum lease payments 6,276 24,262 Less current maturities ( 665 ) ( 5,021 ) Lease liabilities, less current maturities $ 5,611 $ 19,241

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2019
Debt [Abstract]
Schedule Of Short-Term And Long-Term Balances Of Term Loan	June 30, December 31, 2019 2018 Term loan balance $ 221,625 $ 222,750 2.45% Sparkasse Zollernalb (KFW Loan 1) 1,169 1,318 1.40% Sparkasse Zollernalb (KFW Loan 2) 1,637 1,885 Total loan balance 224,431 225,953 Less unamortized loan origination costs ( 8,254 ) ( 9,072 ) Net borrowings 216,177 216,881 Less short-term loan balance ( 1,164 ) ( 1,160 ) Long-term loan balance $ 215,013 $ 215,721

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2019
Revenue Recognition [Abstract]
Disaggregation Of Revenue	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 (Unaudited) (Unaudited) Domestic hospitals $ 36,344 $ 35,139 $ 71,955 $ 68,682 International hospitals 22,532 21,902 43,102 40,951 International distributors 10,365 9,877 19,975 17,887 CardioGenesis cardiac laser therapy 1,898 1,578 3,612 2,924 Total sources of revenue $ 71,139 $ 68,496 $ 138,644 $ 130,444

Stock Compensation (Tables)

Stock Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Stock Compensation [Abstract]
Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options	Three Months Ended Six Months Ended June 30, 2019 June 30, 2019 Stock Options ESPP Stock Options ESPP Expected life N/A 0.5 Years 5.0 Years 0.5 Years Expected stock price volatility N/A 0.39 0.40 0.39 Risk-free interest rate N/A 2.56 % 2.54 % 2.56 %
Summary Of Total Stock Compensation Expenses	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 RSA, RSU, and PSU expense $ 1,936 $ 1,521 $ 3,446 $ 2,469 Stock option and ESPP expense 502 483 973 889 Total stock compensation expense $ 2,438 $ 2,004 $ 4,419 $ 3,358

Income (Loss) Per Common Share

Income (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2019
Income (Loss) Per Common Share [Abstract]
Computation Of Basic And Diluted Income (Loss) Per Common Share	Three Months Ended Six Months Ended June 30, June 30, Basic income (loss) per common share 2019 2018 2019 2018 Net income (loss) $ 2,832 $ 226 $ 2,535 $ ( 3,629 ) Net (income) loss allocated to participating securities ( 19 ) ( 2 ) ( 18 ) 31 Net income (loss) allocated to common shareholders $ 2,813 $ 224 $ 2,517 $ ( 3,598 ) Basic weighted-average common shares outstanding 37,156 36,318 36,968 36,233 Basic income (loss) per common share $ 0.08 $ 0.01 $ 0.07 $ ( 0.10 ) Three Months Ended Six Months Ended June 30, June 30, Diluted income (loss) per common share 2019 2018 2019 2018 Net income (loss) $ 2,832 $ 226 $ 2,535 $ ( 3,629 ) Net (income) loss allocated to participating securities ( 18 ) ( 2 ) ( 18 ) 31 Net income (loss) allocated to common shareholders $ 2,814 $ 224 $ 2,517 $ ( 3,598 ) Basic weighted-average common shares outstanding 37,156 36,318 36,968 36,233 Effect of dilutive stock options and awards 682 931 821 -- Diluted weighted-average common shares outstanding 37,838 37,249 37,789 36,233 Diluted income (loss) per common share $ 0.07 $ 0.01 $ 0.07 $ ( 0.10 )

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Information [Abstract]
Revenues, Cost Of Products And Services, And Gross Margins For Operating Segments	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Revenues: Medical devices $ 51,168 $ 49,313 $ 99,569 $ 92,911 Preservation services 19,971 19,183 39,075 37,533 Total revenues 71,139 68,496 138,644 130,444 Cost of products and preservation services: Medical devices 14,489 13,550 28,315 27,707 Preservation services 9,684 9,095 19,090 17,658 Total cost of products and preservation services 24,173 22,645 47,405 45,365 Gross margin: Medical devices 36,679 35,763 71,254 65,204 Preservation services 10,287 10,088 19,985 19,875 Total gross margin $ 46,966 $ 45,851 $ 91,239 $ 85,079
Summary Of Net Revenues By Product And Service	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Products: BioGlue $ 17,933 $ 17,069 $ 35,155 $ 33,039 JOTEC 17,208 17,205 33,162 31,665 On-X 12,410 11,888 24,141 22,197 CardioGenesis cardiac laser therapy 1,898 1,578 3,612 2,924 PerClot 784 968 1,834 1,940 PhotoFix 935 605 1,665 1,146 Total products 51,168 49,313 99,569 92,911 Preservation services: Cardiac tissue 10,500 9,055 19,430 17,158 Vascular tissue 9,471 10,128 19,645 20,375 Total preservation services 19,971 19,183 39,075 37,533 Total revenues $ 71,139 $ 68,496 $ 138,644 $ 130,444

Basis Of Presentation (Narrativ

Basis Of Presentation (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net present value of operating lease aggrements	$ 24,262
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net present value of operating lease aggrements		$ 22,700

Financial Instruments (Summary

Financial Instruments (Summary Of Financial Instruments Measured At Fair Value) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	$ 1,966	$ 2,192
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	1,458	1,445
Restricted securities	508	747
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	1,966	2,192
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	1,458	1,445
Restricted securities	508	747
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets
Level 2 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents
Restricted securities
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets
Level 3 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents
Restricted securities

Cash Equivalents And Restrict_3

Cash Equivalents And Restricted Securities (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	$ 508,000		$ 508,000		$ 747,000
Gross realized gains or losses on cash equivalents	0	$ 0	0	$ 0
Maturity Date Within Three Months [Member] | Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	$ 508,000		$ 508,000		512,000
Maturity Date Between Three Months And One Year [Member] | Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities					$ 235,000
Minimum [Member] | Maturity Date Between Three Months And One Year [Member] | Money Market Funds [Member] | Measurement Input, Expected Term [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period					3 months
Maximum [Member] | Maturity Date Within Three Months [Member] | Money Market Funds [Member] | Measurement Input, Expected Term [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period			3 months		3 months
Maximum [Member] | Maturity Date Between Three Months And One Year [Member] | Money Market Funds [Member] | Measurement Input, Expected Term [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period					1 year

Cash Equivalents And Restrict_4

Cash Equivalents And Restricted Securities (Summary Of Cash Equivalents And Restricted Securities) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Cash and Cash Equivalents [Line Items]
Cash Equivalents, Cost Basis	$ 40,255	$ 42,236	$ 25,719	$ 40,753
Restricted Securities, Cost Basis	508	747
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash Equivalents, Cost Basis	1,458	1,445
Restricted Securities, Cost Basis	508	747
Unrealized Holding Gains
Cash Equivalents, Estimated Market Value	1,458	1,445
Restricted Securities, Estimated Market Value	$ 508	$ 747

Inventories And Deferred Pres_3

Inventories And Deferred Preservation Costs (Narrative) (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Inventory [Line Items]
Consignment inventory	$ 13	$ 11.2
Domestic [Member]
Inventory [Line Items]
Consignment inventory percentage	50.00%	55.00%
Foreign [Member]
Inventory [Line Items]
Consignment inventory percentage	50.00%	45.00%

Inventories And Deferred Pres_4

Inventories And Deferred Preservation Costs (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventories And Deferred Preservation Costs [Abstract]
Raw materials and supplies	$ 18,496	$ 17,381
Work-in-process	4,382	3,858
Finished goods	22,544	24,239
Total inventories	$ 45,422	$ 45,478

Inventories And Deferred Pres_5

Inventories And Deferred Preservation Costs (Schedule Of Deferred Preservation Costs) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Total deferred preservation costs	$ 32,416	$ 33,174
Cardiac Tissues [Member]
Total deferred preservation costs	16,171	15,972
Vascular Tissues [Member]
Total deferred preservation costs	$ 16,245	$ 17,202

Goodwill And Other Intangible_3

Goodwill And Other Intangible Assets (Schedule Of Carrying Values Of Indefinite Lived Intangible Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 188,106	$ 188,781
In Process R&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	9,325	9,382
Procurement Contracts And Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	2,013	2,013
Trademarks [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	$ 844	$ 844

Goodwill And Other Intangible_4

Goodwill And Other Intangible Assets (Schedule Of Goodwill By Reportable Segment) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Goodwill And Other Intangible Assets [Abstract]
Beginning balance	$ 188,781
Revaluation of goodwill denominated in foreign currency	(675)
Ending balance	$ 188,106

Goodwill And Other Intangible_5

Goodwill And Other Intangible Assets (Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Period Of Definite Lived Intangible Assets) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 134,408	$ 134,999
Accumulated amortization	20,841	16,815
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3,626	3,656
Accumulated amortization	3,030	2,970
Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,059	4,059
Accumulated amortization	2,251	2,107
Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	31,157	31,169
Accumulated amortization	5,825	5,068
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,496	1,154
Accumulated amortization	$ 437	$ 235
Minimum [Member] | Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] | Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] | Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	13 years	13 years
Minimum [Member] | Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	3 years	3 years
Maximum [Member] | Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	22 years	22 years
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	17 years	17 years
Maximum [Member] | Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	15 years	15 years
Maximum [Member] | Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	22 years	22 years
Maximum [Member] | Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	5 years	5 years

Goodwill And Other Intangible_6

Goodwill And Other Intangible Assets (Summary Of Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Goodwill And Other Intangible Assets [Abstract]
Amortization expense	$ 2,557	$ 2,753	$ 5,136	$ 5,487

Goodwill And Other Intangible_7

Goodwill And Other Intangible Assets (Scheduled Amortization Of Intangible Assets For Next Five Years) (Details) $ in Thousands	Jun. 30, 2019USD ($)
Goodwill And Other Intangible Assets [Abstract]
Remainder of 2019	$ 5,186
2020	10,208
2021	10,185
2022	9,639
2023	9,227
2024	9,005
Total	$ 53,450

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Income Taxes [Abstract]
Effective income tax rate	3.00%	269.00%	133.00%	48.00%
Increase in income tax benefit	$ 700	$ 300	$ 1,900	$ 1,400
Valuation allowances against deferred tax assets	3,900		3,900		$ 3,400
Net deferred tax liability	$ 22,700		$ 22,700		$ 23,200

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)item	Dec. 31, 2018USD ($)	Mar. 08, 2019USD ($)	Jan. 01, 2019USD ($)
Operating Leased Assets [Line Items]
Net present value of operating lease aggrements	$ 24,262	$ 24,262
Weighted average discount rate	5.50%	5.50%
Weighted average remaining lease term	5 years 10 months 24 days	5 years 10 months 24 days			6 years
Deferred rent obligations	$ 2,400	$ 2,400
Operating lease, option to terminate, period		29 years
Operating lease, termination option, notice period requirement		2 years
Right-of-use asset	22,413	$ 22,413
Number of subleases | item		2
Sublease income	$ 226	$ 452	$ 910
Minimum [Member]
Operating Leased Assets [Line Items]
Lease terms	1 year	1 year
Maximum [Member]
Operating Leased Assets [Line Items]
Lease terms	11 years	11 years
Lease period of omitted leases		12 months
On-X [Member]
Operating Leased Assets [Line Items]
Right-of-use asset				$ 3,700
Discount rate				5.83%
Accounting Standards Update 2016-02 [Member]
Operating Leased Assets [Line Items]
Net present value of operating lease aggrements					$ 22,700

Leases (Schedule Of Supplementa

Leases (Schedule Of Supplemental Balance Sheet Information Related To Leases) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Leases [Abstract]
Operating lease right-of-use assets	$ 24,828
Accumulated amortization	(2,415)
Operating lease right-of-use assets, net	22,413
Current maturities of operating leases	5,021
Non-current maturities of operating leases	19,241
Total operating lease liabilities	24,262
Finance leases, Property and equipment, at cost	7,627
Finance leases, Accumulated amortization	(1,302)
Finance leases, property and equipment, net	6,325
Current maturities of finance leases	665
Non-current maturities of finance leases	5,611
Total finance lease liabilities	$ 6,276
Weighted average remaining lease term (in years): Operating leases	5 years 10 months 24 days	6 years
Weighted average remaining lease term (in years): Finance leases	11 years
Weighted average discount rate: Operating leases	5.50%
Weighted average discount rate: Finance leases	2.00%

Leases (Summary Of Lease Costs)

Leases (Summary Of Lease Costs) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Leases [Abstract]
Amortization of property and equipment	$ 209	$ 420
Interest expense on finance leases	31	63
Total finance lease expense	240	483
Operating lease expense	1,589	3,153
Sublease income	(226)	(452)	$ (910)
Total lease expense	$ 1,603	$ 3,184

Leases (Schedule Of Supplemen_2

Leases (Schedule Of Supplemental Cash Flow Information Related To Leases) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Leases [Abstract]
Operating cash flows for finance leases	$ 64
Operating cash flows for operating leases	3,311
Financing cash flows for finance leases	$ 350

Leases (Schedule Of Minimum Lea

Leases (Schedule Of Minimum Lease Payments For Finance, Operating, And Sublease Income Leases) (Details) $ in Thousands	Jun. 30, 2019USD ($)
Leases [Abstract]
Finance Leases, Remainder of 2019	$ 437
Finance Leases, 2020	676
Finance Leases, 2021	637
Finance Leases, 2022	582
Finance Leases, 2023	582
Finance Leases, Thereafter	4,075
Finance Leases, Total minimum lease payments	6,989
Finance Leases, Less amount representing interest	(713)
Finance Leases, Present value of net minimum lease payments	6,276
Finance Leases, Less current maturities	(665)
Finance Leases, Lease liabilities, less current maturities	5,611
Operating Leases, Remainder of 2019	2,941
Operating Leases, 2020	6,275
Operating Leases, 2021	5,802
Operating Leases, 2022	3,418
Operating Leases, 2023	2,327
Operating Leases, Thereafter	7,411
Operating Leases, Total minimum lease payments	28,174
Operating Leases, Less amount representing interest	(3,912)
Operating Leases, Present value of net minimum lease payments	24,262
Operating Leases, Less current maturities	(5,021)
Operating Leases, Lease liabilities, less current maturities	19,241
Sublease Income, Remainder of 2019	456
Sublease Income, 2020	921
Sublease Income, 2021	930
Sublease Income, 2022	380
Sublease Income, Total minimum lease payments	$ 2,687

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2018	Dec. 31, 2018	Dec. 01, 2017
Line of Credit Facility [Line Items]
Term loan balance		$ 224,431,000		$ 224,431,000			$ 225,953,000
Credit facility default interest rate		2.00%		2.00%
Credit facility aggregate interest rate		5.58%		5.58%
Credit facility commitment fee percentage				0.50%
Line of credit facility, percentage threshold of principal amount outstanding				25.00%
Interest expense		$ 3,800,000	$ 4,100,000	$ 7,700,000	$ 7,800,000
Government Sponsored Debt [Member]
Line of Credit Facility [Line Items]
Loan term	9 years
2.45% Sparkasse Zollernalb (KFW Loan 1) [Member]
Line of Credit Facility [Line Items]
Term loan balance		1,169,000		1,169,000			1,318,000
Interest rate on amounts borrowed	2.45%
1.40% Sparkasse Zollernalb (KFW Loan 2) [Member]
Line of Credit Facility [Line Items]
Term loan balance		1,637,000		$ 1,637,000			1,885,000
Interest rate on amounts borrowed	1.40%
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate commitments								$ 30,000,000
Credit facility maturity date				Dec. 1, 2022
Credit facility outstanding balance		0		$ 0			0
Credit facility remaining availability		30,000,000		$ 30,000,000
Revolving Credit Facility [Member] | Minimum [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin				3.00%
Revolving Credit Facility [Member] | Minimum [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility margin				4.00%
Revolving Credit Facility [Member] | Maximum [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin				3.25%
Revolving Credit Facility [Member] | Maximum [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility margin				4.25%
Senior Secured Credit Facility [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate commitments								255,000,000
Credit facility outstanding balance								225,000,000
Term Loan [Member]
Line of Credit Facility [Line Items]
Term loan balance		$ 221,625,000		$ 221,625,000			$ 222,750,000	$ 225,000,000
Credit facility maturity date				Dec. 1, 2024
Term Loan [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin				2.25%		3.00%
Term Loan [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility margin				3.25%		4.00%

Debt (Schedule Of Short-Term An

Debt (Schedule Of Short-Term And Long-Term Balances Of Term Loan) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Dec. 01, 2017
Debt Instrument [Line Items]
Term loan balance	$ 224,431	$ 225,953
Less unamortized loan origination costs	(8,254)	(9,072)
Net borrowings	216,177	216,881
Less short-term loan balance	(1,164)	(1,160)
Long-term loan balance	215,013	215,721
2.45% Sparkasse Zollernalb (KFW Loan 1) [Member]
Debt Instrument [Line Items]
Term loan balance	1,169	1,318
1.40% Sparkasse Zollernalb (KFW Loan 2) [Member]
Debt Instrument [Line Items]
Term loan balance	1,637	1,885
Term Loan [Member]
Debt Instrument [Line Items]
Term loan balance	$ 221,625	$ 222,750	$ 225,000

Commitments And Contingencies (

Commitments And Contingencies (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Other Commitments [Line Items]
Sublease income	$ 226	$ 452	$ 910
Unreported loss liability	1,900	1,900	1,700
Recoverable insurance amounts	897	897	693
Property and equipment, net	30,823	30,823	$ 31,028
PerClot [Member]
Other Commitments [Line Items]
Prepaid royalties	1,500	1,500
Net intangible assets	2,200	2,200
Property and equipment, net	1,300	1,300
Maximum [Member]
Other Commitments [Line Items]
Estimated loss	3,700	$ 3,700
Starch Technology Purchase [Member]
Other Commitments [Line Items]
Term of distribution agreement		15 years
Expected future contingent payment amounts	$ 1,000	$ 1,000
Number of notice days		180 days

Revenue Recognition (Disaggrega

Revenue Recognition (Disaggregation Of Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 71,139	$ 68,496	$ 138,644	$ 130,444
Domestic Hospitals [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	36,344	35,139	71,955	68,682
International Hospitals [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	22,532	21,902	43,102	40,951
International Distributors [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	1,898	1,578	3,612	2,924
CardioGenesis Cardiac Laser Therapy [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 10,365	$ 9,877	$ 19,975	$ 17,887

Stock Compensation (Narrative)

Stock Compensation (Narrative) (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	15 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)itemshares	Jun. 30, 2018USD ($)shares	Dec. 31, 2018	Jun. 30, 2019USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Capitalized stock compensation expense	$ 168	$ 132	$ 300	$ 238
ESPP Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, percentage of market price for eligible employees			85.00%
Employees purchased common stock, shares | shares			24,000	36,000		0
RSAs, RSUs, And PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized awards from approved stock incentive plans | shares			492,000	305,000
Aggregate grant date market value			$ 14,600	$ 6,800
Unrecognized compensation costs	16,100		16,100			$ 16,100
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs	$ 2,800		$ 2,800			$ 2,800
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			2 years
Restricted Stock Awards (RSAs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year 6 months
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year 10 months 24 days
Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of performance stock unit grants | item			2
Percentage of target number of shares of common stock granted as Performance Stock Units					80.00%
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			2 years 9 months 18 days
Maximum [Member] | Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units					150.00%
Maximum [Member] | Short-term PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units			150.00%
Maximum [Member] | Long-term PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units			288.00%
Officers [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants of stock options | shares			169,000	219,000

Stock Compensation (Schedule Of

Stock Compensation (Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options) (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options		5 years
Expected stock price volatility		0.40%
Risk-free interest rate		2.54%
ESPP Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	6 months	6 months
Expected stock price volatility	0.39%	0.39%
Risk-free interest rate	2.56%	2.56%

Stock Compensation (Summary Of

Stock Compensation (Summary Of Total Stock Compensation Expenses) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 2,438	$ 2,004	$ 4,419	$ 3,358
RSA, RSU, And PSU Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	1,936	1,521	3,446	2,469
Stock Option And ESPP Option Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 502	$ 483	$ 973	$ 889

Income (Loss) Per Common Shar_2

Income (Loss) Per Common Share (Narrative) (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019
Income (Loss) Per Common Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	158,000	219,000	105,000

Income (Loss) Per Common Shar_3

Income (Loss) Per Common Share (Computation Of Basic And Diluted Income (Loss) Per Common Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Basic (loss) income per common share
Net income (loss)	$ 2,832	$ 226	$ 2,535	$ (3,629)
Net loss allocated to participating securities	(19)	(2)	(18)	31
Net loss allocated to common shareholders	$ 2,813	$ 224	$ 2,517	$ (3,598)
Basic weighted-average common shares outstanding	37,156	36,318	36,968	36,233
Basic loss per common share	$ 0.08	$ 0.01	$ 0.07	$ (0.10)
Diluted (loss) income per common share
Net income (loss)	$ 2,832	$ 226	$ 2,535	$ (3,629)
Net loss allocated to participating securities	(18)	(2)	(18)	31
Net loss allocated to common shareholders	$ 2,814	$ 224	$ 2,517	$ (3,598)
Basic weighted-average common shares outstanding	37,156	36,318	36,968	36,233
Effect of dilutive stock options and awards	682	931	821
Diluted weighted-average common shares outstanding	37,838	37,249	37,789	36,233
Diluted loss per common share	$ 0.07	$ 0.01	$ 0.07	$ (0.10)

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)segment	Jun. 30, 2018USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			2
Revenues | $	$ 71,139	$ 68,496	$ 138,644	$ 130,444

Segment Information (Revenues,

Segment Information (Revenues, Cost Of Products And Services, And Gross Margins For Operating Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Total revenues	$ 71,139	$ 68,496	$ 138,644	$ 130,444
Total cost of products and preservation services	24,173	22,645	47,405	45,365
Total gross margin	46,966	45,851	91,239	85,079
Goodwill	188,106		188,106		$ 188,781
Operating Segments [Member] | Medical Devices [Member]
Segment Reporting Information [Line Items]
Total revenues	51,168	49,313	99,569	92,911
Total cost of products and preservation services	14,489	13,550	28,315	27,707
Total gross margin	36,679	35,763	71,254	65,204
Operating Segments [Member] | Preservation Services [Member]
Segment Reporting Information [Line Items]
Total revenues	19,971	19,183	39,075	37,533
Total cost of products and preservation services	9,684	9,095	19,090	17,658
Total gross margin	$ 10,287	$ 10,088	$ 19,985	$ 19,875

Segment Information (Summary Of

Segment Information (Summary Of Net Revenues By Product And Service) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Product Information [Line Items]
Total revenues	$ 71,139	$ 68,496	$ 138,644	$ 130,444
BioGlue And BioFoam [Member]
Product Information [Line Items]
Total revenues	17,933	17,069	35,155	33,039
JOTEC [Member]
Product Information [Line Items]
Total revenues	17,208	17,205	33,162	31,665
On-X [Member]
Product Information [Line Items]
Total revenues	12,410	11,888	24,141	22,197
CardioGenesis Cardiac Laser Therapy [Member]
Product Information [Line Items]
Total revenues	1,898	1,578	3,612	2,924
PerClot [Member]
Product Information [Line Items]
Total revenues	784	968	1,834	1,940
PhotoFix [Member]
Product Information [Line Items]
Total revenues	935	605	1,665	1,146
Cardiac Tissues [Member]
Product Information [Line Items]
Total revenues	10,500	9,055	19,430	17,158
Vascular Tissues [Member]
Product Information [Line Items]
Total revenues	9,471	10,128	19,645	20,375
Preservation Services [Member]
Product Information [Line Items]
Total revenues	19,971	19,183	39,075	37,533
Operating Segments [Member] | Total Products [Member]
Product Information [Line Items]
Total revenues	51,168	49,313	99,569	92,911
Operating Segments [Member] | Total Preservation Services [Member]
Product Information [Line Items]
Total revenues	$ 19,971	$ 19,183	$ 39,075	$ 37,533